Spironolactone Hepatitis in Primary Hyperaldosteronism
Authors: JOHN SHUCK
Journal: Annals of Internal Medicine (1981)

Brief Reports1 December 1981Spironolactone Hepatitis in Primary HyperaldosteronismJOHN SHUCK, M.D., SHIAO SHEN, M.D., LOREN OWENSBY, M.D., MARTIN LEFTIK, M.D., SAMUEL CUCINELL, M.D.JOHN SHUCK, M.D.Search for more papers by this author, SHIAO SHEN, M.D.Search for more papers by this author, LOREN OWENSBY, M.D.Search for more papers by this author, MARTIN LEFTIK, M.D.Search for more papers by this author, SAMUEL CUCINELL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-95-6-708 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSpironolactone, a 17-spirolactone that competitively inhibits aldosterone, is used in treating secondary hyperaldosteronism (1) and is the preferred drug in treating primary hyperaldosteronism (2). Side effects include gastrointestinal, neurologic, dermatologic, and endocrinologic disturbances. Despite the frequent use of spironolactone in patients with liver disease, no liver toxicity has been reported. We report the case of a patient with primary hyperaldosteronism in whom hepatitis developed secondary to spironolactone therapy.A 53-year-old woman presented in November with hypertension and hypokalemia. She had no medical history, took no medications, and drank no alcohol. Blood pressure was 220/100 mm Hg in both the...References1. MUDGE G. Diuretics and other agents employed in the mobilization of edema fluid. In: GILMAN AG, GOODMAN LS, GILMAN A, eds. The Pharmacologic Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co.; 1980:907-15. Google Scholar2. WILLIAMSDLUHYTHORN GRG. Diseases of the adrenal cortex. In: ISSELBACHER KG, ADAMS RD, BRAUNWALD E, et al, eds. Harrison's Principles of Internal Medicine. 9th ed. New York: McGraw-Hill Book Co.; 1980:1171-736. Google Scholar3. SHERLOCK S. Drug and the liver. In: SHERLOCK S. Diseases of the Liver and Biliary System. 5th ed. Oxford: Blackwell Scientific Publications; 1975:340-82. Google Scholar4. LUDWIG J. Drug effects on the liver. Dig Dis Sci. 1979;24:785-96. CrossrefMedlineGoogle Scholar5. MIYATAKENOMANAKAOMORIMOTOYAMAMURA AKKYY. Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men. Clin Endrocrinol (Oxf). 1978;9:523-33. CrossrefMedlineGoogle Scholar6. CAMPRAREYNOLDS JT. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Am J Dig Dis. 1978;23:1025-30. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Tripler Army Medical Center Honolulu, Hawaii PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySpironolactone-induced hepatitisHepatic fibrin-ring granulomas in giant cell arteritisSpironolactone: A Re-ExaminationMedical Treatment of Low-Renin AldosteronismPrimary AldosteronismDrug effects on the liverDrugs and Liver Disease: A Tabular Compilation of Drugs and the Histopathological Changes That Can Occur in the Liver 1 December 1981Volume 95, Issue 6Page: 708-710KeywordsAlcoholsAldosteroneBlood pressureDrugsHepatitis AHypertensionLiver diseasesToxicity Issue Published: 1 December 1981 PDF DownloadLoading ...